Experimental cancer drug enters human testing for advanced tumors

NCT ID NCT05875168

Recruiting now Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

Summary

This is the first human study testing a new cancer drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial will enroll 540 participants to determine safe dosage levels and see if the drug helps control cancer growth. Researchers will measure side effects, how the body processes the drug, and whether tumors shrink or stop growing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Assistance Publique- de Marseille
RECRUITING

Marseille, 13005, France
Beijing Cancer Hospital
NOT_YET_RECRUITING

Beijing, 100142, China
Cancer Institute Hospital of Jfcr
RECRUITING

Kōtoku, 135-8550, Japan
Centre Léon Bérard
RECRUITING

Lyon, 69008, France
Chu Strasbourg
RECRUITING

Strasbourg, 67091, France
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States

Contact
Hospital Universitari Vall D'Hebron
RECRUITING

Barcelona, 8035, Spain
Hospital Universitario La Paz
RECRUITING

Madrid, 28046, Spain
Hospital Universitario Ramon Y Cajal
RECRUITING

Madrid, 28034, Spain
Hospital Universitario Virgen Macarena
RECRUITING

Seville, 41009, Spain
Huntsman Cancer Institute, University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States

Contact
Institut Claudius Regaud
RECRUITING

Toulouse, 31059, France
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Kansai Medical University Hospital
RECRUITING

Hirakata-shi, 573-1191, Japan

Contact
Kindai University Hospital
RECRUITING

Ōsaka-sayama, 589-8511, Japan
McGill University Health Center
NOT_YET_RECRUITING

Montreal, H4A 3J1, Canada
National Cancer Center Hospital
RECRUITING

Chūōku, 104-0045, Japan

Contact
National Cancer Center Hospital East
RECRUITING

Kashiwa, 277-8577, Japan

Contact
Next Madrid
RECRUITING

Pozuelo de Alarcón, 28223, Spain
Oregon Health & Science University
RECRUITING

Portland, Oregon, 97239, United States
Princess Margaret Cancer Center
RECRUITING

Toronto, M5G2M9, Canada
Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States

Contact
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System
NOT_YET_RECRUITING

Seoul, 03722, South Korea
Shandong Cancer Hospital
RECRUITING

Jinan, 250117, China
Shanghai East Hospital
RECRUITING

Shanghai, 200120, China
The Medical College of Wisconsin, INC
RECRUITING

Milwaukee, Wisconsin, 53226, United States
The Second Peoples Hospital of Neijiang
RECRUITING

Neijiang, 641000, China
UZ Leuven
RECRUITING

Leuven, 3000, Belgium
University of Texas M.D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR